.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,168,218

« Back to Dashboard

Claims for Patent: 8,168,218

Title:Delayed release tablet with defined core geometry
Abstract: A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.
Inventor(s): Vergnault; Guy (Kembs Loechle, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:10/554,538
Patent Claims: 1. A press-coated tablet comprising a core containing 5 mg of prednisone and a coating around the core, said core being disposed within said coating such that the coating thickness about an axis (X-Y) is thicker than the coating about an axis (A-B) orthogonal to (X-Y), wherein the thickness of the coating about the axis (X-Y) is selected such that the coating ruptures upon immersion in an aqueous medium after a period of between about 2 to about 6 hours to release the drug, wherein coating material about the (X-Y) axis is relatively less dense than the coating material disposed about the (A-B) axis and the coating material about the (X-Y) axis is more permissive towards ingress of aqueous media than the coating material disposed about the axis (A-B), and wherein the axis (A-B) is the axis of the direction of movement of the punch used in the press-coating of the tablet: said tablet comprising the following ingredients Core of 5 mg prednisone tablet: Prednisone 8.33% as a percentage by weight in said core; Lactose monohydrate 64.47% as a percentage by weight in said core; Povidone 6.67% as a percentage by weight in said core; Croscarmellose sodium 18.33% as a percentage by weight in said core; Red ferric oxide 0.5% as a percentage by weight in said core; Magnesium stearate Vegetable origin 1.0% as a percentage by weight in said core; Colloidal silicon dioxide 0.5% as a percentage by weight in said core; Coating: Dibasic calcium phosphate dihydrate 50% as a percentage by weight in said coating; Glyceryl behenate 40% as a percentage by weight in said coating; Povidone 8.40% as a percentage by weight in said coating; Yellow ferric oxide 0.1% as a percentage by weight in said coating; Magnesium stearate Vegetable origin 1.0% as a percentage by weight in said coating; Colloidal silicon dioxide 0.5% as a percentage by weight in said coating.

2. The tablet according to claim 1 wherein, upon administration to a patient, the lag time before drug release is 2 to 6 hours.

3. The tablet according to claim 1, said tablet having an in vitro dissolution profile using USP dissolution apparatus No. 2, at a stirring rate of 100 rpm and in a dissolution medium of 500 mL purified water, wherein said dissolution profile comprises a median lag time of about 4 hours with at least 80% of a drug substance being released after 4.5 hours and about 100% of the drug substance being released after 5 hours.

4. The tablet according to claim 1 wherein intra-subject or inter-subject variability in T.sub.max differs by less than +/-20% whether or not a patient is in a fed or a fasted (fed/fasted) state.

5. The tablet according to claim 1 wherein upon administration to a patient the ratio of C.sub.max fed/fasted upon single dosing is 0.7 to 1.43.

6. The tablet according claim 1 wherein upon administration to a patient the ratio of AUC fed/fasted upon single dosing is 0.8 to 1.25.

7. A pharmaceutical package containing a tablet according to claim 1 together with labelling or instructions that the tablet can be taken with or without food.

8. A method of treating arthritic pain, allergies, asthma, Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) by providing to a patient in need of treatment a tablet according to claim 1.

9. A method of preparing a tablet according to claim 1 comprising the steps of: (a) forming a first granulate-containing coating material; (b) forming a core comprising a second granulate-containing core material; and (c) press coating the first granulate-containing coating material around the core.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc